| Press Release | Source: Advanced Cell Technology, Inc. |
New Edition of Definitive Resource in Tissue Engineering Released Today
Thursday August 16, 9:00 am ET
Principles of Tissue Engineering, Third Edition provides a much needed update of the rapid progress that has been achieved in the field, combining the prerequisites for a general understanding of tissue growth and development, the tools and theoretical information needed to design tissues and organs, as well as a presentation by the worlds experts of what is currently known about each specific organ system. The new edition includes greatly expanded focus on stem cells, including adult and embryonic stem cells and progenitor populations that may soon lead to new tissue engineering therapies for heart disease, diabetes, and a wide variety of other diseases that afflict humanity. This up-to-date coverage of stem cell biology and other emerging technologies is complemented by a series of new chapters on recent clinical experience in applying tissue engineering. The result is a comprehensive textbook that we believe will be useful to students and experts alike.
"Dr. Lanza is an industrial expert in the area of stem cells and regenerative medicine, with groundbreaking research that is widely respected throughout the scientific community," said William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology. "He has the unique ability to cut through the confusion and controversy, while articulating the issues and defining the benefits that surround the important research he and others are doing with embryonic stem cells for the betterment of humanity.
"Principles of Tissue Engineering, Third Edition includes contributions by almost 200 scientists and thought leaders, including Douglas Lauffenburger at the Massachusetts Institute of Technology, Bjorn Olsen at the Harvard Medical School, Robert Nerem at Georgia Institute of Technology, Alan Russell at the McGowan Institute for Regenerative Medicine, A. Hari Reddi at the University of California Davis, Ioannis Yannas at the Massachusetts Institute of Technology, George Whitesides at Harvard University, Alan Trounson at Monash Univeristy, Anthony Atala at the Wake Forest Institute for Regenerative Medicine, Charles Vacanti at Harvard Medical School and Massachusetts General Hospital, Eugene Bell at TEI Biosciences, and Laurie Zoloth at Northwestern University, among others.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
For more information, visit www.advancedcell.
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates, Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Source: Advanced Cell Technology, Inc.
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
